Pioneering Therapeutics Targeting Cellular Stress Pathways
Ribon is dedicated to the discovery and development of first-in-class small molecule inhibitors to block cancer cells' fundamental ability to survive under stress.
Learn More
Our Approach
Ribon explores novel areas of disease biology and uses deep expertise in drug discovery to advance its pipeline.
Learn More
Our Targets
Our platform enables us to develop first-in-class therapeutics targeting a wide variety of enzymes that use NAD+ as substrate.
Learn More
Aug 6
Cambridge, MA
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer
Learn MoreJoin our team of experts.
Find Out More